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CHEMOTHERAPY OF UPPER GASTROINTESTINAL CARCINOMA
C. G. MOERTEL, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, U.S.A.
In the Western world, carcinoma of the
pancreas has waxed as gastric cancer has
waned, but both remain as major causes of
cancer mortality. Carcinoma ofthe stomach
dominates the cancer incidence of Asia and
the Soviet Union. Cancers of the liver and
oesophagus ravage the continent of Africa in
almost epidemic proportions. In spite of
the great human need which this problem
presents, there are few areas where the
inadequacies of modern medicine are so
apparent as in the management of upper
gastrointestinal cancer. With all the sophis-
tication of our diagnostic approaches, and
with the ingenuity and heroism ofthe surgical
attack, end-result statistics show that over
95% of patients found to have cancer of the
oesophagus, liver, biliary tract, or pancreas
will die oftheir disease, as will almost 90% of
patients with gastric cancer. These grim
statistics have changed little if at all over the
past 30 years. Until methods can be evolved
for either prevention or for practical detec-
tion of upper gastrointestinal carcinoma in
the asymptomatic state, we must deal with
the problem as the patient presents it to us,
and clearly this is not at a stage amenable to
surgical cure. There would not seem to be a
realistic hope that advances in surgical tech-
nique per se can subsequently change these
statistics. The results of surgery essentially
plateaued a quarter of a century ago. Any
progress, it would seem, must be derived
from nonsurgical approaches. Among these,
radiation therapy is hampered by its regional
restriction and by lack ofspecificity. Immu-
notherapy has, as yet, no track record and
may be largely an illusion. In spite of all its
limitations, the most tangible hope in the
foreseeable future would seem to rest with
chemotherapy.
Chemotherapy of gastrointestinal carci-
noma had its beginnings with the develop-
ment in clinical application of 5-fluorouracil
(5-FU) some 18 years ago. Early reports of
the therapeutic effectiveness ofthis and other
agents presented the reader with such a
confusing labyrinth of claims and counter-
claims that an aura of witchcraft hovered
over those engaged in this field. New drugs
or methods were extravagantly praised by
one investigating group only to be damned
by another. Objective response rates with
5-FU therapy of large bowel cancer, for
example, were reported over the astounding
range of 8 to 85%, even though all investiga-
tors were treating the same neoplasm with
the same drug by the same dosage schedule
(Moertel and Reitemeier, 1969). After these
initial reports, numerous new wrinkles for
administering 5-FU, or its blood-brother
5-fluoro-2'-deoxyuridine (FUdR), were de-
vised and would predictably be advocated by
the devisers as having improved therapeutic
effectiveness. Such claims, however, could
be regarded as little more than testimonials,
since they were not validated by concurrent
control groups. The reader was left- with the
impossible task of judging whether the
reporting investigator at that point in time
was an 8 percenter or an 85 percenter.
Over the past decade, the mediaeval
methodology of our earlier chemotherapy
trials in gastrointestinal cancer has slowly,
and sometimes painfully, given way to more
meaningful and reproducible scientific ap-
proaches. Although some still cling to the
delusion that they can devise historical cont-
rols for retrospective comparisons, ithasnow
become the more accepted practice for com-
parative clinical trials to be prospective and
randomized in design. Considerable progress
has also been made in defining, standardizing,
and communicating the results of clinical
trials. A number of factors have been elu-
cidated which contributed to the striking
variations in response rate reported in the
earlier literature. For almost all areas of
therapeutics it is evident that far-advanced
disease, producing severe physiologic altera-
tion, will be far less likely to respond to
either surgical or medical treatment than an
earlier and less devastating stage of the
disease. This difference, it would seem,
should be seen in even bolder relief for
patients subjected to stressful cytotoxic
drugs with a narrow therapeutic ratio. In
Table I the results ofchemotherapy ofgastro-
intestinal cancer are related to the degree of
disability ofthe patient at the time treatmentB.A.C.R. 17TH ANNUAL GENERAL MEETING
TABLE I.-Relationship ofPerformance Status
to Chemotherapy Response of the Gastro-
intestinal Cancer Patient
A. Gastric cancer
Performance
status* Patients
0-1 66
2 47
3 21
B. Colorectal cancer
Performance
status* Patients
0 97
1 145
2 103
3 15
* ECOG Scale: 0, fully active,
dIisabled.
Objective
response (%)
39
26
4
Objective
response (0O)
31
17
7
7
to 4, totally
was initiated. Disability is scored by the
criteria of the Eastern Cooperative Oncology
Group. A score of0 is fully active, a score of
4, totally disabled. With a gastric carcinoma
patient who is still able to work full or part-
time (score 0 or 1), we get a most respectable
response rate of 390%. For the patient who
is up and about more than half the day but is
unable to work (score 2), the response rate is
almost cut in half. For the patient who is
ambulatory and able to come to the office but
is in a bed or chair most of the day, the
response rate plummets to 400. Precisely
the same relationship is seen in the much
larger group of patients with colorectal
cancer. The fully ambulatory patient
achieves a 31% response rate, the substan-
tially disabled patient a 700 response rate.
We do not treat totally disabled patients, but
if we did, it could be surmised that we would
see essentially no response at all. It can,
therefore, be anticipated that an investigating
group which treats largely ambulatory out-
patients may achieve quite favourable re-
sponses to a given therapeutic regimen. On
the other hand an investigating group who
will either by their philosophy or by the
nature of their practice treat largely disabled
patients may report a very unfavourable
therapeutic experience with precisely the
same regimen.
The criteria chosen by an investigating
group to declare an objective response can
also have great influence on reported results.
Unfortunately, in chemotherapy of gastro-
intestinal cancer, one only rarely sees the
dramatic and complete tumour remissions
that occur in lymphomas or breast cancer.
In the main, we must deal with partial re-
gressions of vaguely defined lumps and livers.
A great deal of faith must be placed in the
objectivity of the investigator, and even then
it must be realized that he is fully subject to
the human frailty of committing error. We
have recently completed a study of repro-
ducibility of measurements oflumps (Moertel
and Hanley, in press). In this study the
investigators measured simulated tumour
masses in pairs of the same size but under
circumstances where the investigators did not
know they were the same. We observed
striking differences in measured sizes, to the
degree that an objective response would
frequently be recorded for a tumour mass that
had not changed at all. The salient facts of
this study, which involved a number of
investigators performing several hundred
measurements, were that, if one used as a
criterion for response a 5000 reduction in the
product of perpendicular diameters, an 8%
response rate would be obtained due to
measuring error alone (in essence, the response
to a placebo). If one used just a 25%
reduction criterion, as has been the practice
in some studies, the placebo response rate
soared to 23%. Whenever therapeutic results
are reported, it is essential to scrutinize
precisely what criteria were employed. It
has now become a common practice to
employ a 50% reduction in the product of
longest perpendicular diameters as the cri-
terion for declaring an objective response.
With such a criterion, one must anticipate a
5 to 100% response due to error. These
erroneous responses can be reduced by more
frequent measurements, oftumour masses, or
by using a longer interval between measure-
ments, and thus taking advantage of the na-
tural growth rate of the neoplasm. Certainly,
any responses based on a25% 0 reduction crite-
rion must be considered as highly suspect.
Another factor that can have a major
influence on reported chemotherapy results
is the method of data analysis. There are
any number of ways of subjecting results to
statistical massage; and if you are skilful at
playing this game, it is remarkably easy to
turn a sow's ear into a silk purse. One of the
most frequent ploys is the unevaluable
patient gambit. The technique is to take
patients who start on treatment but who
become too sick to continue or who die soon
after and discard these from your analysis as
" unevaluable ". In some reports one-third
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TABLE II.-Comparative Survival Times Among Specific Types of Gastrointestinal
Adenocarcinomas Measured From Time ofProof of Incurable Cancer
Primary tumour
Hepatoma (cirrhosis)
Gall bladdler
Pancreas
Stomach
Duodenum
Bile ducts
Ampulla of Vater
Jejunum and ileum
Carcinoid (small bowel)
Islet cell carcinoma
No. of patients
15
114
145
307
15
59
22
28
35
6
Survival
Median (months) Range
2-0
2-5
3-5
4 0
5a0
5 0
6-0
9 0
30 0
57 0
1 week to 40 months
1 week to 23 months
4 weeks to 10 years
4 weeks to 12 years
3 weeks to 13 months
2 weeks to 43 months
6 weeks to 39 months
5 weeks to 34 months
8 weeks to 23 years
5 months to 13 years
to one-half of the original patients are swept
under the table in this manner, and this, of
course, greatly inflates the response rate.
Such a legerdemain, however, would seem to
be a rather questionable practice. If a
patient becomes too sick to continue treat-
ment, or ifhe dies, he would seem as evaluable
as he can get. Indeed, it is quite possible
that adverse effects of treatment could have
contributed to his rapid deterioration. If a
patient is selected for treatment and initiated
on treatment, he deserves a place in the
denominator.
The natural history of untreated upper gastro-
intestinal carcinoma
Before discussing treatment, we should
first have some concept of the natural history
of the disease we are treating, at least in
terms of survival. This provides us with an
essential background against which we can
view our therapeutic accomplishments. Table
II shows the longevity of untreated patients
with upper gastrointestinal carcinoma,
measured from the time of proof of unre-
sectable disease. There is a striking range in
longevity among the specific tumour types,
ranging from the virulent hepatomas, com-
plicating cirrhosis, and carcinoma of the
gallbladder, to the remarkably indolent
carcinoid tumours and islet-cell carcinomas.
It can also be seen that there is a striking
range in longevity within each tumour type.
It is worth emphasis that some of these
patients can have exceedingly long survivals
with no treatment whatsoever. In Table III
the more specific characteristics ofthe patient
and his disease that have a significant in-
fluence on prognosis are considered. Here
we have employed our more frequent upper
gastrointestinal carcinomas, cancer of the
TABLE III.-Clinical Characteristics and
Survival in Patients with Unresectable
Gastric and Pancreatic Carcinoma
MC
Characteristic
Exteint of disease
Regional
Abdominal
Hepatic
Extra-abdominal
Location of primary
(pancreas)
Head
Body
Tail
Grade ofanaplasia (Broder's)
1 and 2
3 and 4
Interval, resection to
recurrence
1 to 5 months
6 to 11 months
12 to 23 months
24 months and over
Palliative surgery
None
Bypass
Resection
-edian survival (months)
Gastric Pancreatic
6-0
3-0
2-5
2-0
5-0
4-0
2-5
2-0
4-0
3-0
2-5
7-0 5-5
4-0 3-0
2-0
3-0
6-0
6-5
3.5
4-5
6-0
2-0
4-5
stomach and cancer of the pancreas. These
determinants are particularly important in
providing appropriate stratification for rando-
mized trials. We found that age and sex of
the patient had little influence on longevity
except that the very elderly, 75 years or
older, tended to have shorter survivals. As
might be expected, the patients with only
regional disease lived longer than those with
distant abdominal spread, who lived longer
than those with hepatic metastasis, who lived
longer than those with extra-abdominal
metastasis. Location of the primary lesion
in the stomach had no influence, but patients
with carcinoma of the head of the pancreas
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lived longer than those with primaries in the
body or tail-perhaps because the tumour in
the head is heralded at an earlier stage by the
development of obstructive jaundice. Also,
as might be expected, patients with highly
anaplastic neoplasms had a much more rapid
course than those with a well-differentiated
microscopic morphology. Again, perhaps
proving the obvious, malignant disease that
is indolent in its earlier phases tends to be
indolent throughout its course. In gastric
cancer, this can be demonstiated by the
interval from resection of the primary with
curative intent to proof of metastases; in
pancreatic carcinoma, by a less precise mea-
sure, the duration of symptoms. If the
surgeon performs a palliative procedure, such
as a bypass or resection, the patient does live
longer. This may be artifactual, however,
since in the patient with very advanced
disease, the surgeon may consider a palliative
attempt either injudicious or technically
impossible.
We have also found that assessments of
immune function have prognostic signifi-
cance. Elevated immunoglobulins indicate
a very short survival. The patient with
lesser numbers of T cells or impaired T-cell
function also lives a shorter period of time.
Such patients with impaired laboratory
parameters of immune function, however,
are also patients with advanced stages of
disease associated with impaired nutrition
and impaired performance status. We are
not convinced at this time thattheseelaborate
and expensive immunologic assays tell us
more than can be discerned by already
apparent clinical determinations.
Treatment of gastrointestinal cancer with 5-
fluorouracil
5-fluorouracil (5-FU) was the first chemo-
therapeutic agent to prove capable of
inducing tumour regressions of gastrointes-
tinal adenocarcinoma in the hands of all
investigators reporting its use. Although the
true therapeutic value of this agent may be
questioned, it has nevertheless served as a
stimulus and catalyst for clinical research in
the treatment of this most common group of
neoplasms.
In an attempt to improve the therapeutic
ratio of 5-FU, this agent has been delivered
through every natural or artificial orifice into
almost every available human lumen by
every conceivable dosage schedule. Pre-
dictably, each new approach has been
lauded by the initiator as more effective, less
toxic, and eminently suitable for office
practice. Equally predictably, none of these
claims have stood the test of a controlled
clinical trial. Noteworthy conclusions of
these controlled trials have been the follow-
ing: (1) the nucleoside of 5-FU, 5 fluoro-2'-
deoxyuridine (FUdR), does not have any
significant clinical advantage over 5-FU
(Reitemeyer, Moertel and Hahn, 1965); (2)
slow infusion ofthese fluorinated pyrimidines
adds expense and nuisance to the treatment
procedure but not improved therapeutic
efficacy (Reitemeyer and Moertel, 1962;
Moertel, Reitemeyer and Hahn, 1967; Moertel
et al., 1972); (3) the oral route of administra-
tion of 5-FU is associated with erratic drug
absorption and significantly inferior thera-
peutic effect, regardless of administration
schedule (Hahn et al., 1975; Bateman et al.,
1975; Ansfield, 1975) and (4) weekly adminis-
tration of 5-FU is significantly inferior to the
loading course method (Ansfield, 1975).
Table IV would seem to put the fluori-
nated pyrimidine question into proper pros-
pective. Here we have related the objective
response rates to 5-FU or FUdR, regardless
TABLE IV.-Toxicity and Objective Response
to Fluorinated Pyrimidine Therapy
A. Gastric cancer (110 patients)
Nadir of leucopenia Objective response (%)
4000/mm3 26
4000 to 1500/mm3 41 P < 0 05
1500/mm3 133
B. Colorectal cancer (381 patients)
Nadir of leucopenia Objective response (%)
4000/mm3 9
4000 to 1500/mm3 23 SP < 0 01
1500/mm3 153
of how they were given, to degree of toxicity
as measured by nadir of leucopenia. It is
evident that if no toxicity at all is experi-
enced, results are inferior to those when
patients are treated to mild or moderate
toxicity. On the other hand, treating to
severe or nearly lethal toxicity does not
improve, but rather seems to detract from,
therapeutic effect. It must be concluded
that 5-FU or FUdR are not cancer-specific
drugs. Any significant effect on the neo-
plastic tissue must be achieved at the price
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of some toxic effect to normal tissues. A
severe cytotoxic effect, however, seems to be
more detrimental to host than to tumour.
CHEMOTHERAPY OF GASTRIC AND
PANCREATIC CARCINOMA
Single agent therapy
To this date, our primary task in chemo-
therapy of pancreatic and gastric carcinoma
has been a search for single agents that will
show some evidence of significant activity
when used alone and, hopefully, will form the
basis for a later evolution of combination
drug therapy regimens. In this quest, we
have followed largely an empirical road.
Table V shows our single-agent experi-
ences with advanced pancreatic carcinoma.
These have been singularly discouraging.
TABLE V.-Chemotherapy of Advanced Pan-
creatic Carcinoma: Single Agents
Objective
Regimen Patients response
5-FU 39 6 (15%)
BCNU 18
Methyl CCNU 15 2 (13%)
Actinomycin D 13
MTX (i.v.) 13 1 (8%)
Adriamycin 11 1 (9%)
Fluorometholone 7
MTX (Oral) 6
Misc. (< 3 each) 12 1*
* Single patient treated with FUdR.
Median
duration of
response
(months)
2-5
8-5
5-FU produces only a minimum response
rate and the responses are exceedingly tran-
sitory. Bischloroethyl nitrosourea (BCNU)
and methyl chloroethyl cyclohexyl nitro-
sourea (methyl CCNU) have been equally
discouraging. None ofthe other single drugs
at which we or others have looked show
anything more than an occasional spurious
response.
In quite remarkable contrast are our
results with single-agent therapy of gastric
carcinoma (Table VI). Here we have much
more respectable response rates and these
with agents of a variety of specific activities.
5-FU produces a very acceptable rate and
duration ofregression. Surprisingly we have
achieved an excellent response rate with
adriamycin, a drug that is essentially worth-
less for colorectal cancer. Even with this
TABLEVI.-ChemotherapyofAdvancedGastric
Carcinoma: Single Agents
Objective
Regimen Patients response
5-FU 72 19 (26%)
BCNU 33 6 (18%)
Adriamycin 29 11 (38%)
Methyl CCNU 15 2 (13%)
Fluorometholone 14 1 (7%)
CCNU 11 -
Mitomycin C 11 3 (27%)
Camptothecin 7
Hydroxyurea 6 1
Streptonigrin 5 1
Median
duration of
response
(months)
4.5
4 0
5 0
4 0
2-7
brighter picture in gastric carcinoma, how-
ever, it would seem quiteclearthatsingle-drug
therapy has not provided substantive benefit
in any type ofgastrointestinal cancer. Much
of our more recent efforts have, therefore,
been directed towards combination drug
therapy. As a rule of thumb, we feel that
for drugs to be effective in combination, they
must show some evidence of activity when
used alone. Combining ineffective drugs has
inevitably led to ineffective combinations.
Also, we have felt that one must be able to
use the constituent drugs together with a less
than proportionate summation of their toxic
effects. Our first study in this regard was an
evaluation of combinations involving 5-FU,
Mitomycin C, and BCNU. In pilot studies,
we found that when Mitomycin C and BCNU
were used in double combination, you could
use only one-half of a full dose of each.
Mitomycin C and 5-FU looked a bit better,
permitting two-thirds of a full dose of each.
5-FU and BCNU look particularly attractive
since 75% of the full dose could be combined
with no more toxicity than using either ofthe
drugs alone. With this background, we then
initiated a controlled evaluation, randomizing
215 patients with gastrointestinal cancer to
treatment with each of the single drugs, with
each of the three possible double drug com-
binations, and with the triple drug combina-
tion (Reitemeier, Moertel and Hahn, 1970).
Regrettably, none of the combinations per-
formed any better than 5-FU alone and most
of them were worse. We were particularly
disappointed with combined 5-FU and BCNU
which had demonstrated only a minor and
insignificant increase in duration of response.
In this study, as was common practice in that
era, we put all the specific types of gastro-
intestinal cancers into the same pot in the
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belief that they would all respond the same.
In recent years, it has become evident that
this is an erroneous assumption. All gastro-
intestinal cancers are not alike. When we
looked at our responses of specific cancers to
combined 5-FU and BCNU, we found that
the response rate for colorectal cancer was
abominable and this negative observation has
subsequently been confirmed by Lokich and
associates. On the other hand, the response
rate in a very small group of gastric and
pancreatic carcinomas looked remarkably
good. With this encouragement we expanded
our controlled study to a much larger group of
167 gastric and pancreatic cancer patients
randomized to 5-FU alone, BCNU alone, and
the 5-FU/BCNU combination (Table VII)
TABLE VII.-A Controlled Evaluation of
Combined 5-FU and BCNU Therapy for
Advanced Gastric and Pancreatic Carcinoma
Primary Objective
site Regimen Patients response (0o)
Stomach 5-FU 28 29
BCNIJ 23 17
5-FU BCNU 34 41
Pancreas 5-FU 31 16
BCNU 21 0
5-FU + BCNU 30 33
(Kovach et al., 1974). In gastric cancer, 41O%
of patients responded to the combination
compared to 290% and 170% with the single
drugs. In pancreatic cancer it was 3300 vs
16% and 000. If we take the liberty of
grouping these two sets of data and calling
them all upper gastrointestinal carcinoma,
then the superiority of the 5-FU/BCNU
combination approaches statistical signi-
ficance. But to be really clinically signifi-
cant, objective response must translate into
a favourable change in the natural history of
the disease. The only objective means of
measuring this is in terms ofpatient survival.
When we analysed our survival curves for
carcinoma of the pancreas, we found that all
overlapped and they were essentially the same
as that of clinically matched untreated
patients. For gastric cancer, however, the
picture was a bit brighter. BCNU alone
clearly added nothing, but both 5-FU and
the combination were associated with im-
proved early suvival. This quickly faded
with 5-FU, but it continued with the com-
bination. At one and one-half years 27% of
these patients with far advanced gastric
cancer treated with 5-FU plus BCNU were
still living compared to only 700 with either
single drug or with no treatment at all.
With this glimmer of success, we then
turned our attention to the newer nitrosourea
analogues, particularly to methyl CCNU.
This drug has the advantage of an oral route
of administration whereas BCNU has to be
given i.v. Also, methyl CCNU seems to
have some therapeutic advantage in animal
models. In the Eastern Cooperative Onco-
logy Group, therefore, we initiated a study in
gastric cancer comparing methyl CCNU alone
with the combination of 5-FU and methyl
CCNU (Moertal et al., in press). In this
study we threw in the wrinkle of cyclophos-
phamide induction, and that was a total
failure (Table VIII). The combination of
TABLE VIII.-Therapy of Advanced Gastric
Cancer: Methyl CC.INU Alone vs 5-FU
Methyl CCNU; with An Evaluation of
Cyclophosphamide (CTX) Induction
Regimen Patients
CTX -- methyl CCNU 30
Methyl CCNU alone 37
CTX--5-FJU+ methyl CCNU 30
5-FU+methyl CCNU 30
* 5-FU + methyl CCNU superior
regimens, P < 0* 05.
Objective
response (%)
7
8
20
40*
to all other
5-FU and methyl CCNU, however, garnered
a 400% objective response, significantly
superior to that achieved with methyl CCNU
alone. In addition, survival of patients
treated with the combination was also signi-
ficantly superior to that for patients treated
with the single drug. Further confirmation
of the effectiveness of this combination has
come from studies by the Southwest Oncology
Group (Baker et al., 1975) (Table IX). This
study involved a spectrum of upper gastro-
intestinal carcinomas and compared the
TABLE IX.-A Comparison of 5-FU +
Methyl CCINU vs 5-FU Alone in Upper
Gastrointestinal Carcinoma (Southwest On-
cology Group), 5-FU given by wleekly
injection
Regimen
5-FU alone
5-FU + Methyl CCNU
Objective
Patients response (00)
22
53
9
25
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5-FU/methyl CCNU combination with 5-FU
used alone. In this study the weekly method
for 5-FU was employed; and perhaps because
of this, overall response rates were scaled
down. But again, there was a substantial
advantage for the combination in comparison
to 5-FU alone. With 3 successive studies
showing improvement in response rate with
the combination compared to single drug
treatment, and with 2 successive studies
demonstrating significant improvement in
survival, I believe we are now justified in
concluding that combined 5-FU and nitro-
sourea therapy is a significant advance in the
management ofgastric cancer. The question
remains to be answered whether we can do
more with this combination than just shrink
lumps and delay death. Combined 5-FU and
methyl CCNU as an adjuvant to potentially
curative gastric cancer surgery is now under-
going clinical trial in the Gastrointestinal
Tumour Study Group, the Eastern Coopera-
tive Oncology Group, and the Veterans
Administration Surgical Adjuvant Group.
Combination chemotherapy of pancreatic car-
cinoma
Table X shows overall experience with
combination chemotherapy of advanced pan-
creatic carcinoma. The best results we have
TABLE X.-Chemotherapy of Advanced
Pancreatic Carcinoma with Drug Com-
binations
Regimen
5-FU + BCNU
5-FU + strepto-
zotocin
5-FU + cyclo-
phosphamide
5-FU + fluoro-
metholone
5-FU + Mito-
mycin C
Patients
21
11
Median
duration of
Objective response
response (months)
7 (33%) 5-5
2 (18%) 6-0
10 1 (10%)
7 1 (14%)
3
Chemotherapy ofoesophageal carcinoma
Squamous cell carcinoma is not an un-
common malignant disease and surgical
results have been characterized by an
operative mortality rate that exceeds the cure
rate. It is surprising that chemotherapy
experience with this disease has been so
meagre. Bleomycin has perhaps had the
largest overall clinical application. The
reported response rates with this drug,
however, are far from impressive. Among
14 consecutive patients we treated with
bleomycin as a single agent, we did not
observe any evidence of therapeutic activity.
Our only other trial has been with the nitro-
sourea, CCNU. Here we observed 3 re-
sponses among 19 patients treated and these
persisted for periods of only 2, 3 and 9
months. Certainly this is nothing approach-
ing a therapeutic accomplishment. Our pre-
sent effort in oesophageal carcinoma must
be in Phase II evaluations of single drugs,
with the hope that we can unearth at least a
few agents with some degree of activity that
can form the constituents of rational drug
combinations.
Chemotherapy of hepatocellular carcinoma
(Table XI)
We have had occasional brief responses
with systemic 5-FU, and others have noticed
TABLE XI.-Chemotherapy of Hepatoma
Duration
Objective of response
Regimen Patients response (months)
5-FU 8 3 (37%) 2, 2, 9
Adriamycin 7 2 2, 3j
Mitomycin C 4 1 5
BCNU
Fluorometholone
Methotrexate
Emetine
5-FU + BCNU
3
3
2
2
19 7 (37%) 2, 2, 4, 4, 25+,
44+, 75
obtained to date have been with the 5-FU/
BCNU combination, and this, as mentioned
above, did not produce any improvement in
patient longevity. The other combinations
employed have added little ifanything to the
meagre accomplishments of 5-FU used alone.
The primary task in pancreatic carcinoma
remains a search for significant therapeutic
activity.
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occasional brief responses with 5-FU or
FUdR by hepatic artery infusion. Studies
at the University of Wisconsin (Davis,
Ramirez and Ansfield, 1974), however, have
shown that the expensive and cumbersome
intra-arterial approaches really contribute
nothing significant to patient survival. Of
special interest to us has been the quite
impressive response rate we have achieved
with combined 5-FU and BCNU therapy.
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Thirty-seven per cent of our patients have
shown tumour regression and 3 of these were
of very long duration. In a recently com-
pleted joint African and American study of
hepatoma therapy (Falkson, Moertel and
Lavin, 1976), adriamycin as well as the
combinations of 5-FU plus each of the 2
nitrosoureas, methyl CCNU and streptozoto-
cin, all produced a significant improvement in
survival of hepatoma patients when com-
pared to treatment with 5-FU alone. We are
now most interested in pursuing the 3
drug combinations of 5-FU, methyl CCNU
and adriamycin.
Chemotherapy of the carcinoid tumour and the
malignant carcinoid syndrome
The malignant carcinoid syndrome pro-
vides a dramatic event in oncologic practice.
We must, however, restrain our zeal to
expose these patients to the hazards of cyto-
toxic drugs at an early stage of the disease.
This tumour is exceedingly indolent and
patients can frequently have several years of
productive life before the disease causes
them any real disability. Although the
carcinoid syndrome may be fascinating to the
physician, its early stages seldom cause the
patient more problems than an occasional
blush and mild diarrhoea which can be con-
trolled with standard symptomatic meas-
ures. All the patients listed Table XII,
TABLE XII.-Chemotherapy of Carcinoid
Tumour
Regimen
5-FU
Actinomycin D
Streptozotocin
Phenylalanine mustard
Fluorometholone
Adriamycin
Mitomycin C
Cyclophosphamide (CTX)
5-FU + streptozotocin
CTX + streptozotocin
5-FU + BCNU
BCNU + streptozotocin
Patients
20
9
6
6
5
4
3
2
13
11
2
1
Objective
response
6 (30%)
1 (11%)
3 (50%)
1 (25%)
6 (46%)
1 (90)
therefore, had far advanced disease and yet
5-FU alone produced a reasonable rate of
response. A few years ago we reported
therapeutic activity with streptozotocin
(Moertel et al., 1971), and this has subse-
quently been confirmed by others. Re-
sponses to this agent, however, are usually
incomplete and short-lasting. Since strepto-
zotocin has hardly any haematological toxi-
city, it can be combined with other cytotoxic
drugs in essentially full doses of each agent.
Our rate of response with a cyclophos-
phamide/streptozotocin combinationwasvery
disappointing. It was, however, exceedingly
favourable for the 5-FU/streptozotocin com-
bination. Both of these combinations are
currently undergoing more extensive evalua-
tion in an Eastern Cooperative Oncology
Group Study.
Great caution must be exercised in offer-
ing effective chemotherapy to the patient
with the malignant carcinoid syndrome, since
this may trigger offa severe and life-threaten-
ing carcinoid crisis. We have not found any
serotonin antagonist to combat this compli-
cation effectively. In treatment of the
carcinoid syndrome, it is therefore our policy
to initiate therapy with one-half the pro-
jected therapeutic dose in patients who have
florid manifestations of the syndrome or who
have urine 5-hydroxyindolacetic levelsgreater
than 150 mg/24 h.
Chemotherapy of islet-cell carcinoma
Much akin to the carcinoid is the islet-cell
carcinoma, a tumour with a variety of
functional capacities. As in the carcinoid,
we have seen an occasional response with
5-FU (Table XIII). Streptozotocin, how-
TABLE XIII.-Chemotherapy of Islet-cell
Carcinoma
Regimen Patients
Streptozotocin
Methyl CCNU
Tubercidin
Adriamycin
5-FU
Streptozotocin
+ 5-FU
8
6
5
4
3
10
Duration
Objective of response
response (months)
3 7, 91, 16-+
2 2, 14
2 2,3
1 9
1 8
7 3, 31, 4+, 8i,
12+, 53+,
55+
ever, has written a new chapter in the
treatment of these neoplasms. Among a
collected series of 56 patients with hor-
monally active islet-cell carcinomas reported
by Broder and Carter (1973), functional
improvement was observed in 64% and
objective tumour regression was seen in 37%.
We have observed 3 objective responses
among 6 patients, one of which was most
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dramatic, in a patient near death with a
fulminating pancreatic cholera syndrome,
showing a high rate response to the 5-FU/
streptozotocin combination. Some of these
responses have also been of a very striking
nature and of very long duration. This com-
bination is currently being compared in a
controlled study with streptozotocin used
alone.
CONCLUSIONS
Until the very recent past, chemotherapy
of upper gastrointestinal cancer was largely
an academic endeavour with no evidence of
substantive contribution to the overall popu-
lation of patients treated, whether measured
in terms of symptomatic palliation or im-
proved survival time. Now, however, it is
possible to recognize a few definite steps of
progress. Refinements of methodology have
allowed data to be communicated in a
meaningful way. In comparative trials, the
randomized prospective design now permits
believable differences to become apparent
without the cloud of subjectivity and arte-
facts that obscures the testimonial-type
reports or the study based only on historical
controls. Although 5-FU probably remains
the most active single drug in upper gastro-
intestinal cancer, definite antineoplastic effect
has been demonstrated for a number of other
agents. It does, however, seem obvious that
no single drug therapy has been of significant
value for the upper gastrointestinal cancer
patient, whatever the stage of the disease at
which it is administered. Following the path
that has led to success in leukaemia, lym-
phoma and breast cancer, increasing emphasis
is now placed on combination chemotherapy
regimens for upper gastro-intestinal cancer.
Combined 5-FU and nitrosourea therapy has
increased response rate for carcinomas of the
stomach, pancreas, and liver to the 30 to
40% range. In gastric carcinoma and in
hepatoma this has also been associated with
improved patient survival. Combined 5-FU
and streptozotocin has produced even higher
response rates in the carcinoid tumour and
islet-cell carcinoma.
Even though these results may seem
exciting, they are certainly far from our
ultimate objectives. Responses in advanced
disease are still transient and all the patients
still die of their disease. None of our ap-
proaches for advanced and metastatic upper
gastrointestinal cancer are of sufficient value
to justify offering as standard or routine
treatment. We must continue to regard all
patients at this stage of their disease as
subjects for clinical research.
It is obvious that the only hope for
increasing cure rates for upper gastro-
intestinal cancer in the foreseeable future lies
intheapplicationofchemotherapy, orperhaps
immunotherapy, to the patient who has been
brought to the point of minimal tumour
burden by surgical resection. Surgical adju-
vant chemotherapy attempts in the past have
been notable only for their failures. The
chemotherapy applied under these circum-
stances, however, has had very little evidence
of therapeutic activity, e.g. thiotepa, 5-FU,
FUdR and Mitomycin C. With the signi-
ficantly greater activity now demonstrated
by our combination regimens, it would seem
appropriate that new efforts at surgical
adjuvant therapy be undertaken.
In treating the patient with upper
gastrointestinal cancer, it is evident that
neither surgeon, radiotherapist, nor onco-
logist have accomplished anything of real
value by working alone or in sequence, nor
is there any realistic hope that such solo
performances will produce any substantive
future accomplishment. If, however, we
can offer our patients the best ofall concerned
disciplines, working together in carefully
designed protocols, then I feel we can con-
fidently anticipate significant improvements
in the results of treatment for tomorrow's
upper gastrointestinal cancer patient.
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